⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20308638 | 0.72 | PPARG (0.31) | — | |
| SCHEMBL16138831 | 0.65 | TP53 (0.31) | — | |
| SCHEMBL3682174 | 0.65 | TP53 (0.31) | — | |
| SCHEMBL7640236 | 0.65 | TP53 (0.35) | — | |
| SCHEMBL1847374 | 0.64 | SMN1; SMN2 (0.37) | — | |
| SCHEMBL8594429 | 0.64 | SMN1; SMN2 (0.37) | — | |
| SCHEMBL7637933 | 0.62 | — | — | |
| SCHEMBL1942272 | 0.62 | LMNA (0.37) | — | |
| SCHEMBL576391 | 0.61 | — | — | |
| SCHEMBL13941928 | 0.59 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025105354-A1 | COMPOSITION FOR SEMICONDUCTOR PRODUCTION | 三菱瓦斯化学株式会社 | 2025-05-22 | — | — | WO | claimed |
| WO-2025105354-A1 | COMPOSITION FOR SEMICONDUCTOR PRODUCTION | 三菱瓦斯化学株式会社 | 2025-05-22 | — | — | WO | disclosed |
| US-10100076-B2 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | GILEAD PHARMASSET LLC (US) | 2018-10-16 | — | — | US | disclosed |
| US-9670175-B2 | Protected succinates for enhancing mitochondrial ATP-production | Neurovive Pharmaceuticals AB (SE) | 2017-06-06 | — | — | US | disclosed |
| WO-2017060418-A1 | PROTECTED CARBOXYLIC ACID-BASED METABOLITES FOR THE TREATMENT OF MITOCHONDRIA-RELATED DISEASES | NEUROVIVE PHARMACEUTICAL AB (SE) | 2017-04-13 | — | — | WO | disclosed |
| US-20150259317-A1 | PROTECTED SUCCINATES FOR ENHANCING MITOCHONDRIAL ATP-PRODUCTION | MITOPHARM LTD (GB) | 2015-09-17 | — | — | US | disclosed |
| US-20140057863-A1 | MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | GILEAD SCIENCES, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| EP-2251015-B1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | GILEAD PHARMASSET LLC (US) | 2013-02-20 | — | — | EP | disclosed |
| US-20110269707-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation | PHARMASSET, INC. | 2011-11-03 | — | — | US | disclosed |
| EP-2251015-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | Pharmasset, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| EP-1411954-A2 | MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | Pharmasset Limited (BB) | 2004-04-28 | — | — | EP | disclosed |
| US-20030087873-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | PHARMASSET, INC. | 2003-05-08 | — | — | US | disclosed |
| WO-2002032920-A2 | MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | PHARMASSET LIMITED (BB) | 2002-04-25 | — | — | WO | disclosed |